

Claims

1. Use of a composition comprising an inhibitor of IRAK1 in the manufacture of a medicament for treating triple negative breast cancer in a patient who is resistant to paclitaxel therapy, wherein the level of IRAK1 protein in a tumour test sample from the patient has been determined to be elevated in comparison to a normal tissue control sample and wherein the inhibitor is a ginsenoside.
2. The use according to claim 1, further comprising a pharmaceutically acceptable carrier.
3. The use according to any one of claims 1 or 2, wherein the patient is administered a further anti-cancer agent or treatment.
4. A method for determining a patient's cancer-free survival, the patient having been diagnosed with triple negative breast cancer and who is receiving paclitaxel therapy, or who has previously received or is receiving paclitaxel therapy and has relapsed, the method comprising assessing the level of IRAK1 protein in a tumour sample obtained from the patient and comparing the level to an IRAK1 level in a normal tissue control sample, wherein a normal IRAK1 level is considered to indicate a >90% chance of 10 year breast cancer free survival with standard therapy, and an elevated level is considered to indicate a <85% chance of 10 year breast cancer free survival.